October 24, 2020
Business News

Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million

BASEL, Switzerland–()–Polyneuron Pharmaceuticals AG, a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced a CHF 14 million extension of the Series A, bringing the total to CHF 36.5 million. HBM Healthcare Investments has joined the consortium of investors in the Series A, led by Sofinnova Partners, and which included New Enterprise Associates (NEA) and other private investors.

Polyneuron will use the proceeds to advance its lead product candidate PN-1007, a potential treatment for anti-MAG neuropathy, a serious nervous system disease with a high unmet medical need, through Phase I/IIa clinical development….

Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Halloween Promotion: VideoProc V3.9 Revamped with M3U8 Download and iPhone 12 Support
PhaseBio Provides Pemziviptadil (PB1046) Program Update
post featured image
Ant Group IPO pricing ‘history’s largest’, says Alibaba’s Jack Ma – Fox Business